Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168148 | 1.00 | MMP1 (0.42) | MMP1MMP2MMP9MMP12TDP1 | |
| SCHEMBL148443 | 0.86 | GPBAR1 (0.46) | TDP1BRD4CREBBPNPC1RAB9A | |
| SCHEMBL5091923 | 0.86 | TDP1 (0.45) | TDP1ESR1ESR2NPC1RAB9A | |
| SCHEMBL4556983 | 0.86 | TDP1 (0.45) | TDP1ESR1ESR2NPC1RAB9A | |
| SCHEMBL1949591 | 0.79 | LMNA (0.41) | NAAANPC1 | |
| SCHEMBL1883113 | 0.78 | CES2 (0.41) | TDP1RAB9AALDH1A1TSHRMAPK1 | |
| SCHEMBL1280223 | 0.77 | LMNA (0.40) | NAAANPC1 | |
| SCHEMBL1727857 | 0.77 | GLA (0.32) | NPC1GLASMN1; SMN2 | |
| SCHEMBL8418687 | 0.76 | DDB1 (0.48) | TDP1RAB9AALDH1A1SMN1; SMN2DDB1 | |
| SCHEMBL5816927 | 0.76 | POLB (0.35) | NPC1SMN1; SMN2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924392-B2 | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-02 | — | — | US | disclosed |
| US-20030225099-A1 | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-04 | — | — | US | disclosed |
| US-6605625-B2 | Antiarrhythmia agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-12 | — | — | US | disclosed |
| US-20030013719-A1 | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225099-A1 | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | PON1, CYP3A43, KCNH1 | MMP1 1371/4885MMP2 1794/4885MMP9 2238/4885 |
| US-20030013719-A1 | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | PON1, CYP3A43, KCNH1 | MMP1 1371/4885MMP2 1794/4885MMP9 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.